Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit

GlobeNewswire10/18 20:30

Oragenics Shares Are Trading Higher After the Company Provided a Corporate Update on Its 2024 Progress Including Developments of ONP-002, Its Lead Candidate for Concussions.

Benzinga10/09 21:14

Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation

Oragenics10/09 12:00

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

GlobeNewswire10/08 20:45

EXCLUSIVE: Oragenics Completes Key FDA-Recognized Study For Concussion Drug Candidate

Benzinga10/08 20:30

12 Health Care Stocks Moving In Wednesday's Intraday Session

Benzinga09/25 22:42